Obesity Drug News Today: Retatrutide, Costs, and Trends

Just a few months ago, the cost of a month’s supply of Wegovy felt out of reach for many, but a federal price deal and a breakthrough trial result are now reshaping expectations. In May 2026, Eli Lilly reported retatrutide phase 3 results showing nearly 30% weight loss in 68 weeks, outperforming other GLP-1s (Scientific American).

Retatrutide weight loss at 68 weeks: nearly 30% (Scientific American) ·
Wegovy injection lowest dose cash price: $349/month (NBC News) ·
Medicare negotiated Ozempic monthly price: $276.78 (STAT)

Eight key data points, one pattern: prices are coming down but access remains a puzzle.

What is the latest news on weight loss drugs?

What major developments occurred in 2026?

• November 2025: Trump administration announced a price deal with Novo Nordisk and Eli Lilly, lowering out-of-pocket costs for cash-pay patients (The White House).
• May 2026: Eli Lilly reported retatrutide phase 3 results showing nearly 30% weight loss at 68 weeks (Scientific American).
• June 2026: Drugmakers race to develop new GLP-1 drugs, with Pfizer and others advancing candidates (STAT).

The year’s biggest story is the convergence of policy and science. The White House price deal, combined with strong trial data, signals a turning point in obesity care.

Which drugmakers are leading the race?

• Novo Nordisk: current leader with Wegovy and Ozempic, developing oral amycretin (Scientific American).
• Eli Lilly: dominates with Zepbound and Mounjaro, lead candidate retatrutide showing best weight loss (NBC News).
• Pfizer: advancing oral aleniglipron in trials (STAT).

The competitive landscape is shifting. While Novo Nordisk and Eli Lilly hold the lead, Pfizer and others are investing heavily to capture a share of the growing GLP-1 market, which JPMorgan expects to expand rapidly in 2026 (JPMorgan).

The implication: The next 12 months will determine whether Lilly’s retatrutide or Novo’s oral pill reshapes the market, but the real battle is over affordability.

What new obesity drugs are coming?

What injectable drugs are in development?

• Retatrutide (Eli Lilly): once-weekly injection, phase 3 results showing nearly 30% weight loss (Scientific American).
• Wegovy injection (Novo Nordisk): currently approved, but lower pricing under new deal (NBC News).
• Zepbound (Eli Lilly): already approved, additional formulations in trials (STAT).

What oral drugs are being tested?

• Amycretin (Novo Nordisk): oral GLP-1 pill, expected to be cheaper if approved (NBC News).
• Aleniglipron (Pfizer): oral GLP-1 in clinical trials (STAT).
• At least 14 other new weight loss drugs in clinical trials, per industry analysts (JPMorgan).

Oral GLP-1s represent a major advance — they eliminate injections and could improve adherence, especially among older patients who may struggle with injections.

What this means: If oral candidates succeed, the market could double within five years, but trial failures remain a risk.

Is Mounjaro better than Ozempic?

Three key differences, one theme: both work, but the choice depends on your treatment goal.

In head-to-head trials, Mounjaro showed greater weight reduction, but Ozempic has a longer safety track record. The choice often comes down to insurance coverage and tolerability.

The pattern: For pure weight loss, Mounjaro edges ahead; for diabetes with weight loss, Ozempic remains the standard. Both have significant gastrointestinal side effects.

Why are older people quitting GLP-1?

What side effects are driving discontinuation?

• Nausea, vomiting, diarrhea — the most common reasons older patients stop (NBC News).
• Older adults may have higher sensitivity due to slower metabolism and polypharmacy (Scientific American).
• Weight loss plateau often leads to frustration and discontinuation (JPMorgan).

Are cost and access factors?

• Despite price cuts, many Medicare patients still face high out-of-pocket costs (STAT).
• Insurance coverage gaps force some to pay full retail or stop (Atlanta Medical).
• Older patients on fixed incomes are particularly vulnerable to price volatility (The White House).

The combination of gastrointestinal side effects and cost pressures creates a perfect storm for older patients, many of whom do not stay on therapy long enough to see significant weight loss.

The catch: Even with lower prices, adherence remains a challenge. The drugs work, but only if patients can tolerate them and afford them.

How much will Wegovy cost in 2026?

What is the current price of Wegovy?

• Wegovy injection lowest dose cash price: $349/month (NBC News).
• Wegovy pill lowest dose cash price: $149/month (if approved) (NBC News).
• Ozempic/Wegovy via TrumpRx: $350/month (The White House).

How did the Trump deal affect pricing?

• The November 2025 deal aims to lower out-of-pocket costs for cash-pay patients by setting a price cap for GLP-1s (The White House).
• Medicare negotiated price for injectable GLP-1s: $245/month originally proposed, but actual numbers vary by drug (STAT).
• Cash-pay patients through direct-to-consumer platforms expected to pay about $350/month (Atlanta Medical).

The Trump deal set a ceiling, not a floor. Many patients still face higher prices depending on insurance status and dose. For a detailed price breakdown, see our guide on GLP-1 obesity drugs price comparison.

What this means: Wegovy’s effective cost in 2026 depends on whether you pay cash, have Medicare, or use a marketplace. The gap between the advertised $149 pill and the real out-of-pocket cost can be significant.

We anticipate additional retatrutide trials to conclude in 2026, and may seek FDA approval as soon as that year.

— Eli Lilly representative, as reported by NBC News

This agreement will lower out-of-pocket costs for GLP-1 medications and expand access for cash-paying patients.

— White House fact sheet (The White House)

The weight loss drug landscape in 2026 is defined by two forces: scientific breakthroughs and political will. Retatrutide could become the most effective obesity drug ever approved, but its impact will be muted if affordability barriers remain. For older patients on fixed incomes, the choice is clear: either push for broader Medicare coverage, or risk losing access to a generation of transformative treatments.

Related reading: GLP-1 obesity drugs price comparison · New GLP-1 weight loss drugs coming stronger than Wegovy Zepbound

For a broader look at how these medications compare, check out the latest obesity drug news from Houston Brief.

Frequently asked questions